Alex Malter, MD
Internal Medicine · Juneau, AKNPI 1174549596
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by GSK at 40.5% of the total. 2025 is the largest year on record at $170, 4.0 times the $43 reported in 2023.
Across 14 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$141
- Novartis$54
- Regeneron Healthcare Solutions, Inc.$37
- Lilly USA, LLC$23
- Viiv Healthcare Company$22
- AstraZeneca$21
- plus $50 from 3 others
What the payments were for
- Food & beverage$348100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $141 |
| Novartis | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Lilly USA, LLC | 1 | $23 |
| Viiv Healthcare Company | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Pfizer | 1 | $18 |
| AbbVie | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$348 in reported general payments places this provider in the 70th percentile of 124 internal medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $151,769 |
| JardianceEmpagliflozin | 59 | $52,824 |
| JanuviaSitagliptin Phosphate | 58 | $52,656 |
| OzempicSemaglutide | 30 | $49,083 |
| XareltoRivaroxaban | 30 | $47,377 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $44,483 |
| MounjaroTirzepatide | 25 | $30,128 |
| EntrestoSacubitril/Valsartan | 12 | $23,374 |
| FarxigaDapagliflozin Propanediol | 21 | $22,473 |
| Spiriva RespimatTiotropium Bromide | 21 | $21,141 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $15,613 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $15,480 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,438 |
| Atorvastatin Calcium | 441 | $4,662 |
| Metoprolol Succinate | 218 | $3,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $151,769142 claims |
| Lilly USA, LLCMounjaro | $23 | $30,12825 claims |
| NovartisEntresto | $54 | $23,37412 claims |
| AstraZenecaFarxiga | $21 | $22,47321 claims |
| GSKBreo Ellipta | $141 | $15,48014 claims |
| AbbVieLumigan | $17 | $3,87513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 124 internal medicine providers in Alaska.
Other internal medicine in Juneau
- Nathaniel HaddockJuneau$1K
- David BarnesWasilla$11K
- Loretta LeeAnchorage$8K
- Andrew CapGlennallen$7K
- Susan HeverlingAnchorage$6K
- Laurie MontanoAnchorage$6K
- Michele O FallonAnchorage$6K
- John BostonWasilla$6K
- Alvaro RosalesAnchorage$4K
- Robin MillerAnchorage$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.